Clinical Trial Update: S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial comparing S-1 versus 5-FU bolus in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sanofi | Conditions: Pancreatic Neoplasm, Neoplasm Metastasis | Phase 3 | Status: TERMINATED